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Background: Arenavirus matrix protein Z plays an important role in virus budding and is able to generate
enveloped virus-like-particles (VLPs) in absence of any other viral proteins. In these VLPs, Z protein is associated to
the plasma membrane inner surface by its myristoyl residue. Budding induction and vesicle formation properties
can be exploited to generate enveloped VLPs platform. These structures can be designed to carry specific antigen
in the inner side or on the surface of VLPs.
Vaccines based on VLPs are a highly effective type of subunit vaccines that mimic the overall structure of virus
particles in absence of viral nucleic acid, being noninfectious.
In this work we assayed the capacity of Junin Z protein to produce VLPs carrying the green fluorescent protein
(eGFP), as a model antigen.
Results: In this report the Junin Z protein ability to produce VLPs from 293T cells and its capacity to deliver a
specific antigen (eGFP) fused to Z was evaluated. Confocal microscopy showed a particular membrane bending in
cells expressing Z and a spot welded distribution in the cytoplasm. VLPs were detected by TEM (transmission
electron microscopy) and were purified from cell supernatant. The proteinase protection assay demonstrated the
VLPs integrity and the absence of degradation of the fused antigen, thus indicating its internal localization. Finally,
immunization of mice with purified VLPs produced high titres of anti-eGFP antibodies compared to the controls.
Conclusions: It was proved that VLPs can be generated from cells transfected with a fusion Junin virus Z-eGFP
protein in absence of any other viral protein, and the capacity of Z protein to support fusions at the C-terminal,
without impairing its budding activity, allowing vehiculization of specific antigens into VLPs.
Keywords: Virus-like particles, Antigen delivery, Arenavirus, Z proteinBackground
The Arenavirus Z protein is considered the matrix pro-
tein of this virus family [1]. It comprises three main
regions that contain different domains: the Amino-end
(Myristoylation Domain), the Core (RING Domain), and
Carboxyl-end (Late Domain) [2]. Among the several
functions described for this small protein (11 kDa) it can
be highlighted its inhibitory effect on viral RNA replica-
tion and transcription through its interaction with the L
protein [3,4] as well as its capability of interacting and
recruiting the viral nucleoprotein [5,6]. Other interesting
proposed properties may include: translation inhibition* Correspondence: cristinaborio@gmail.com
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reproduction in any medium, provided the orthrough interactions with cellular factors like the pro-
myelocytic leukemia protein (PML) [7], the eukaryotic
translation initiation factor eIF4E [8], and downregula-
tion of IRF7 expression in arenavirus-infected plasmacy-
toid dendritic cells (pDCs) [9]. At the late steps of the
infection cycle, Z is the driving force of arenaviral bud-
ding [10]. This activity is mainly conducted by two
motifs found at the Z C-terminal domain, PTAP in the
New World arenaviruses and/or PPPY in the Old World
arenaviruses. These motifs, called late domains, mediate
the interaction with cellular factors of the multivesicular
body pathway (MVB) and drive the viral budding from
the plasma membrane of arenaviruses and other viruses
[9,11]. It has been previously reported that the expres-
sion of the Z protein alone is sufficient to induce the re-
lease of Z-containing enveloped particles in Lassa fevertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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myristoylation in the glycine 2 residue is an important
modification of Z. Mutations at this site completely
abolish its capacity of driving the budding process,
reflecting the importance of the interaction with mem-
brane to promote budding [15,16]. For other matrix pro-
teins, it has been reported that insertion of epitopes with
a length of 20–30 amino acids still allows VLPs produc-
tion and does not interfere with its budding activity [17].
Budding induction and vesicle formation properties can
be exploited to generate enveloped VLPs. These VLPs
structures can be designed to carry T or B cell epitopes
which can be recognized by mature T and B lymphocytes
from adaptive immune response [17]. Currently, many
successful viral vaccines are predominantly based on live
attenuated or inactivated viruses. The induced immune
responses are similar to those from natural infections and
often these vaccines are effective after a single dose. How-
ever, the reversion of attenuated viruses and incomplete
inactivation of killed virus vaccines are the major manu-
facturing concerns. Subunit vaccines are safer than live
attenuated and inactivated vaccines, but often single pro-
teins, when expressed and purified in the absence of other
viral components, are less immunogenic than those that
are incorporated into infectious particles. In this sense, the
vaccines based on VLPs are a highly effective type of sub-
unit vaccines that mimic the overall structure of virus par-
ticles in absence of viral nucleic acid, being absolutely
noninfectious [18].
In this work we assayed the capacity of the Junin Z pro-
tein as a VLP-forming protein carrying the green fluores-
cent protein (eGFP) as a model antigen. To accomplish
this, we cloned and expressed in mammalian 293T cells
the recombinant Z-eGFP from the Z protein of Junín
Virus Candid#1. In addition, we demonstrated that the fu-
sion of Z protein to a heterologous protein like eGFP, does
not interfere with its budding capacity in mammal cells,
evaluating the VLP generation by microscopic and im-
munologic methodologies. Furthermore, we produced and
purified Z-eGFP derived VLPs to evaluate their ability to
induce an immune response in vivo.
Results
Expression of Z-eGFP on 293T cells
The pZ-eGFP plasmid was constructed based on the
commercial vector pEGFP-N3 (Clontech) for mamma-
lian cell expression of Z-eGFP protein under the regula-
tion of CMV promoter. Transient transfection of 293T
cells with this plasmid resulted in a high level expression
of Z-eGFP protein (37.9 kDa). We analyzed the expres-
sion of both Z-eGFP and eGFP (26.9 kDa) proteins by
confocal fluorescence microscopy and the distributions
were similar in both cases, only with minor differences
(Figure 1). In Z-eGFP transfected cells (Figure 1B) weobserved a dotted pattern of fluorescence distributed
around the cytoplasm (close to the plasma membrane)
which was completely absent in control cells (Figure 1A).
These patterns were clearly ascertained in optical sections
(Figure 1B’ and Additional file 1: Figure S1A). The main
difference between Z-eGFP and eGFP expression resides
in the plasma membrane bending in Z-eGFP transfected
cells. This phenomenon is clearly observed on the Z stack
as well as in the optical sections (Figure 1B’) but it was
also absent in the corresponding control cells (Figure 1A
and 1A’).
Purification of Z-eGFP virus like particles
In order to determine if the fluorescent signal corre-
sponded to the full length Z-eGFP protein, the cell
lysate fraction was analyzed by western blot and the Z
protein was detected (Figure 2A), with a molecular
weight of approximately 38 kDa, corresponding to the
size of the fusion protein. To detect virus like particle
formation, we analyzed the pellet after ultracentrifuga-
tion through a sucrose cushion of supernatants har-
vested from pZ-eGFP transfected cells and, as shown
in Figure 2A, we localized the Z-eGFP in the pelleted
material.
To analyze if Z-eGFP was included into organized struc-
tures resembling VLPs, the pellet obtained after ultracen-
trifugation was subjected to a protease protection assay
(Figure 2B). In this assay, untreated samples were com-
pared to samples treated either with proteinase K alone or
with proteinase K in the presence of Triton X-100 to allow
permeabilization. Treatment with proteinase K had no
effect on the Z-eGFP protein, whereas the addition of
Triton X-100 destroyed the lipid envelope and therefore
enabled the degradation of Z-eGFP by proteinase K. These
results clearly demonstrate that Z-eGFP is located in the
inner region of VLPs and is preserved from degradation by
the lipid membrane. Finally, this sample was analyzed by
transmission electron microscopy with immunogold label-
ing (Figure 2C and D, and Additional file 2: Figure S2),
which provided evidence for the presence of irregular elec-
tron dense structures of 40 to 150 nm of diameter coincid-
ing with the expected appearance of VLPs labeled with
gold particles. These particles were absent in the control
group (data not shown). Furthermore, in Additional file 2:
Figure S2 we observed a structure, compatible with mem-
brane debris, containing Z-EGFP. Also in the TEM picture,
unlabeled VLPs were observed, probably due to the sample
preparation protocol, which lacks a permeabilization step.
GFP-specific IgG antibody response
To determine the humoral immune response to GFP,
Balb/C mice were immunized with the previously puri-
fied Z-eGFP VLPs, in the absence of adjuvant. Total
GFP-specific IgG antibodies were assayed by ELISA on
Figure 1 (See legend on next page.)
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Figure 1 Confocal fluorescence microscopy of 293T transient transfected cells. A. Z-serie of 293T control cells transfected with peGFP-N3,
followed by an optical section and digital zoom of the yellow rectangle. A´. Optical section. B. Z-serie of 293T cells transfected with pZ-eGFP,
followed by an optical section and digital zoom. B´. Optical section. Red arrows indicate the membrane bending and the spot welded
distribution. The bar in each figure represents 10 μm.
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mice belonging to VLPs immunized group had gener-
ated an immune response to GFP, while maximum titres
were achieved by day 35 (1:1000 on average). The arith-
metic means of each group at day 35 were plotted in
Figure 3, where it was possible to evidence that the IgG
response obtained by Z-eGFP VLPs was significantly
more robust than the soluble antigen, or the Triton X-
100 treated Z-eGFP VLPs.
Discussion
In this study we analyzed the Junin Virus Z-eGFP fusion
protein expression and, in more detail, its budding cap-
acity on 293T cells, aiming to the development of a plat-
form for antigen vehiculization.
First, we assayed the transient transfection of 293T
cells with pZ-eGFP (Figure 1), where we detected high
levels of Z-eGFP expression with a homogeneous distri-
bution. However, the resolution achieved by confocal
microscopy allowed us to detect some regions of con-
centrated protein which are located near the nucleus,
where it would be expected to find the endoplas-
mic reticulum membrane system, and a spot weldedFigure 2 Z-eGFP virus like particles detection and characterization. A.
293T cells. Lane 1. 293T untransfected monolayer (control). 2. 293T monola
ultracentrifugated supernatant of untransfected 293T cells (control). 4. Pelle
pZ-eGFP. (Sup) pelleted material from supernatant. B. Protease protection a
transfected 293T cells. Western Blot with anti-Z inmunoglobuline of the pe
with proteinase K to final concentration of 0.04 μg/μl, 0.08 μg/μl and 0.4 μ
Transmission electron microscopy with immunogold labelling of the pellet
supernatant of pZ-eGFP transfected cells. The red arrow indicates the golddistribution around the cytoplasm. These spots can be
explained by the previously described interaction be-
tween Z and the PML protein. The PML forms nuclear
bodies, and it has been shown that Z alone is sufficient
to redistribute PML from a nuclear punctuate to a cyto-
plasmic punctuate pattern [7]. Also these agreggates
could be late endosomal compartments such as multive-
sicular bodies (MVB) containing intraluminal vesicles
derived from Z-eGFP, as it has been described for retro-
viruses [19]. These vesicles would then be transported to
the plasma membrane, where the fusion of the MVB
allowed the release of the intraluminal vesicles, in this
case the Z-eGFP derived VLPs. This hypothesis of Z-
eGFP associated to membrane vesicles is supported by
the fact that arenavirus Z protein is myristoylated. The
wild type distribution of Z protein is spot welded around
the cytoplasm and homogeneously distributed across the
plasma membrane. However, in studies with a mutant Z
protein at the myristoylation essential amino acid (gly-
cine 2) a diffused pattern mainly with a perinuclear dis-
tribution was shown [15]. The same was demonstrated
for the gag protein of HIV [20]. Therefore it has been
proved that Z localization is membrane associated [15],Western Blot with anti-Z inmunoglobulines of Z-eGFP expression in
yer transfected with pZ-eGFP. (Cell) Cell lysate 3. Pellet of the
t of the ultracentrifugated supernatant of 293T cells transfected with
ssay of Z-protein-containing particles in the supernatant of pZ-eGFP
llet of the ultracentrifugated supernatant of transfected cells, treated
g/μl, with or without Triton X-100, or untreated (lane 1). C and D.
obtained by ultracentrifugation through a sucrose cushion of the
labelling. The bar in each figure represents 100 nm.
Figure 3 GFP-specific total serum IgG antibody response. A.
Groups of Balb/C mice were intramuscularly immunized twice with
Z-eGFP VLPs, Z-eGFP VLPs treated with Triton X-100, GFP and PBS
(negative control). Blood samples collected at day 35 were 50-fold
diluted and used to determine GFP-specific total IgG by ELISA.
Optical densities (490 nm) are expressed as the arithmetic means
plus standard error. ANOVA one-way analysis (Tukey's Multiple
Comparison Test) of variance was used to determine statistical
significance between different samples.*; P<0.05. ns; not significant
(P>0.05). B. The immunization schedule used in this experiment.
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protein from the place of synthesis and myristoylation,
to the plasma membrane. However, Kentis et al.(2002)
[21] described that bacterially expressed LCMV Z pro-
tein appeared to self assemble into ordered protein
structures of 500 Å that approximate in size to the pro-
tein aggregates observed in vivo. These arrangements
were obtained in vitro from purified Z protein expressed
in a prokaryotic system where some posttranslational
modifications, like myristoylation, do not occur.
On the other hand, the morphology of the membrane
on cells transfected with pZ-eGFP clearly differed from
control cells (eGFP). In the first case, it was possible toobserve the bending of the plasma membrane or bud-
ding initiation regions, suggesting an intact budding ac-
tivity of Z-eGFP protein. This membrane bending has
also been observed using confocal fluorescence micros-
copy for other viruses like AcMNPV baculovirus [22]
and MLV retrovirus [23].
Results depicted in Figure 2 showed that recombinant
Z-eGFP protein was able to form vesicles at the plasma
membrane in a similar way as Z protein alone, suggest-
ing that the fusion of a 238 amino acid protein, like
eGFP, did not impair the budding capacity of Z. It is a
common feature of matrix polypeptides like HIV gag
protein or influenza M1 protein to conserve their bud-
ding capability when they are fused to small epitopes
[17]. However, it is not frequent that proteins mainly
involved in budding activities can support the introduc-
tion of large proteins without having its budding cap-
acity impaired. Capul and de la Torre (2008) [24] have
recently described that the fusion of the small (185
amino acids) luciferase from Gaussia princeps to Arena-
virus Z protein resulted in a quimeric protein that
retained budding activity. Considering the budding cap-
acity of quimeras containing Z from Junín virus and a
heterologous protein (in this study, GFP), other proteins
could be coupled to Z generating a tool for antigen
delivery.
According to the electron microscopy images the VLPs
produced by Junin virus Z protein in 293T cells have a
relative size similar to the Junin virion (50 to 100 nm)
(Figure 2C and D) as well as an irregular shape, which is
consistent with observations made for other arenaviruses
[12,25,26].
Some important features for an immunization deliv-
ery vehicle are a safe generation procedure in a low bio-
safety level lab and the protection of the internal
molecules from degradation. According to this, VLPs
lack of any replicative function and the results show
that particles are closed and internal polypeptides (in
this study, Z-eGFP) protected from extracellular pro-
teases. In order to analyze the VLPs immunization cap-
acity, an assay using Balb/C mice was performed. A
satisfactory humoral immune response was induced
against the eGFP contained within the VLPs. This re-
sponse was detected within a few days after the booster
immunization reaching a maximum title by day 35.
However, in the same conditions, neither completely
disrupted Z-eGFP VLPs nor purified eGFP immunized
mice showed a detectable IgG response (Figure 3), sug-
gesting a better performance for intact VLPs.
There are many reports showing that the particulate
nature improves the immunogenicity of the proteins
included in or delivered by VLPs [27,28]. So, it is not
surprising that VLPs described here improved the re-
sponse against the antigen contained within the particle.
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protein did not induce a detectable humoral response.
Traditional VLPs as well as pathogens have highly re-
petitive surfaces and usually induce strong antibody
responses because they can cross-link B cell receptors
with high efficiency [29]. The vesicles generated here
show an important difference with other VLP systems
since the protein is contained mainly within the vesicle,
as shown by the protease protection assay (Figure 2B).
In order to induce production of antibodies, protein
must be exposed so that it can be recognized by B cells
and this might happen by partial disruption of VLP
membrane with exposition of antigen and direct stimu-
lation of B cells. Although the size of VLPs (50–100 nm)
would allow their access to lymphatic vessels and their
transport directly to draining lymph nodes [28,30] we
can not exclude the possibility that cell-associated trans-
port of native protein might be involved in activation of
B cells as well. This phenomenon, that involves internal-
ization and recycling of native antigen to cell surface,
has been described for macrophages associated to the
subcapsular sinus [31-33], dendritic cells [34-36] and
follicular dendritic cells [37]. This mechanism would be
important in dendritic cells, which have both non-
degradative and degradative antigen uptake pathways,
allowing them not only to prime T cells but also to
present native antigen to B cells. Some authors have
demonstrated that this mechanism is dependent of
interaction of immune complexes with inhibitory Fc
receptors [38] but a recent publication from Le Roux
et al. demonstrates that DCs have the ability to regurgi-
tate unprocessed antigen which poses another B-cell ac-
tivation mechanism [39].
Any of these possibilities or more probably a combin-
ation of several of them would allow inducing an anti-
body response against eGFP, despite the fact that the
protein is contained within the VLPs (Figure 3). Similar
results were obtained by Cubas et al. (2009) [40] after
immunizing mice with SHIV VLPs (SIV Gag + HIV
SF162 Env), since they observed an antibody response
both to external envelope protein (Env) and to the in-
ternal gag protein.
Although the immunological response induced needs
further characterization the results suggest that this sys-
tem might be used as a platform to deliver foraneous
antigens or even chimeric heterologous antigens, which
can induce an antibody response even in the absence of
any exogenous adjuvant.
Conclusions
In summary, the results obtained here indicate that Z
protein from Junin virus can support fusions at the C-
terminal without impairing its budding activity. This is
suitable for the production of VLPs and could be usedfor vehiculization of heterologous proteins from other
pathogens acting as promising immune stimulators.
Methods
Cell culture
For the transient expression of recombinant Z protein
we used human embryonic kidney cells transformed
with adenovirus type 5 DNA, designated 293T [41].
Cells were grown in RPMI 1640 (Invitrogen) supplemen-
ted with 10% fetal bovine serum at 37°C in a 5% CO2
atmosphere.
Transfection of 293T cells
Cell monolayers (80% confluence) were washed with PBS
and transfected with the plasmid using PolyFect transfec-
tion reagent (Qiagen) following the manufacter instruc-
tions. The ratio of DNA (μg) to PolyFect (μl) was 1:10 for
both 30 mm dishes (2 μg of DNA) and 60 mm dishes (8 μg
of DNA). In all cases the DNA was previously purified with
Qiagen Plasmid Mini kit. The samples were analyzed by
Western blot and Fluorescence Microscopy as described
below, 48 and 72 h post-transfection.
Fluorescence microscopy
Transfected 293T cells with either pZ-eGFP or peGFP-
N3 were grown on glass cover slides as indicated above.
After 48 h, cells were fixed with 4% (wt/vol) formalde-
hyde in PBS for 15 min at room temperature. Images
were captured using a confocal microscope Olympus
FluoView FV1000 at 600x magnification, and analyzed
using Olympus FluoView 2.0 software.
Western blot
The samples were separated by SDS-PAGE (12-15%
polyacrylamide gel) and blotted onto nitrocellulose
membranes (Hybond P+, Amersham Pharmacia) in Tris-
glycine buffer containing 20% (v/v) methanol. To avoid
non-specific binding of the antibodies, the membranes
were blocked by incubating with 5% (w/v) skimmed
powder milk in PBS for 2 h at 37°C. For the primary
antibody incubation the blocked membrane was probed
with a 1/1,000 dilution of a polyclonal antiserum specific
for the Z protein on PBS 2% casein at 37°C for 1 h, fol-
lowed by a horse radish peroxidase conjugated goat anti-
rabbit IgG (Santa Cruz Biotechnology) incubation,
diluted 1/10,000 on PBS 0.1% Tween-20 at 37°C for 1 h.
Between steps, the membrane was washed three times
with PBS 5 minutes. For Dot blot assays, the samples
were vacumm blotted onto a nitrocellulose membrane
and treated as mentioned for Western blot.
VLPs purification by sucrose cushion ultracentrifugation
Supernatants of previously transfected cells were col-
lected and clarified from cellular debris by low speed
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After clarification, VLPs present in supernatants were
pelleted through a 30% (w/v) sucrose cushion at 96,000 g
for 2 h at 4°C. Pellets were then resuspended in PBS.
Corresponding monolayers were harvested in ProteoJET
Mammalian Cell Lysis Reagent (Fermentas) and used as
control samples in Western blot assays.
In order to obtain large quantities of Z-eGFP VLPs,
multiple 75 cm2 culture flasks at 80% confluence were
transfected with pZ-eGFP and culture media was collected
up to the third passage. Following the first step of ultra-
centrifugation the pellets were pooled and resuspended on
PBS for further treatment with proteinase K. An extra
ultracentrifugation step (96000 g for 2 h at 4°C) was made
for the removal of the proteinase K, foreign proteins and
defective VLPs from the preparation. The pellet was resus-
pended in PBS and used to immunize mice.
Protease protection assay
Pellets obtained from pZ-eGFP transfected cells were
treated with 0.4 μg, 0.08 μg or 0.04 μg of proteinase K
(Fermentas) alone or with a combination of proteinase K
and 1% Triton X-100 for 30 min at 37°C. After the incu-
bation the reaction was stopped with 100 mM PMSF
and boiled for 10 minutes. Samples were then analyzed
by SDS-PAGE and Western Blot.
Transmission electron microscopy (TEM)
A drop of the purified VLPs suspension was deposited
on a formvar-carbon-coated nickel grid for 1 min. The
samples were negatively stained with 2% phosphotungs-
tic acid and examined in a Phillips EM 301 electron
microscope.
TEM-immunogold
After ultracentrifugation, VLPs were resuspended in PBS
containing 4% paraformaldehyde. A drop of the suspen-
sion was deposited on a formvar-carbon-coated nickel
grid for 1 min and washed six times with PBS. The grids
were then treated with dilution buffer i.e. PBS containing
0.5% bovine serum albumin and 0.1% Tween during 30
min followed by washing with PBS. Grids were then
incubated for 1 h with rabbit anti-Z polyclonal IgG 1/300
in dilution buffer for 1 hour. The grids were washed six
times with PBS and incubated further for 1 h with a don-
key anti-rabbit IgG antibody coupled to 12 nm gold beads
(Invitrogen) 1/20 in dilution buffer. Finally, grids were
washed six times with PBS, fixed for 10 min in 2% glutar-
aldehyde, negatively stained with uranil acetate and exam-
ined by TEM.
Mice immunization
Male inbred Balb/C mice aged 6 weeks (4 per group)
were immunized intramuscularly with 5 μg of Z-eGFPVLPs in 100 μl PBS, twice threat a three weeks interval.
To determine the effect of VLP integrity on its inmuno-
genicity, VLPs were disrupted by treatment with 1% Tri-
ton X-100 and used to immunize mice as a control
group. Two additional controls groups were included:
mice immunized with either 5 μg of soluble GFP protein
or PBS alone. Blood samples were collected on days 0, 7,
14, 21, 28 and 35 for analysis of immune responses and
mice were sacrified on day 42 postimmunization. Sera
were stored at −20°C until use.
Evaluation of humoral immune response
Ninety six-well microtiter plates (Nunc, Maxisorpt
Glostrup, Denmark) were coated with 0.5 μg of GFP
protein in coating buffer, ie: 0.1 M bicarbonate buffer
pH 9.6, overnight at 4°C. Plates were blocked with PBS
containing 1% of casein at 37°C, for 1 h. After this and
the following steps the plates were washed three times
with washing solution, i.e.: PBS, 0.5 M NaCl, 0.2% (v/v)
Triton X-100. Fifty microliters of each serum sample
from immunized animals diluted in sample buffer (i.e.:
1% (w/v) casein in washing solution) were added to the
antigen coated wells and incubated at 37ºC for 1 h.
Bound antibodies were detected with peroxidase-
conjugated anti-mouse IgG (Pierce) in sample buffer at
37°C for 1 h and were then revealed with ortho-
phenylene diamine (OPD, Sigma Chemicals Co) [42].
Additional files
Additional file 1: Figure S1. Individual optical sections of transfected
293T cells. A. Optical sections of pZ-eGFP transfected cells, from section
21–67. B. Optical sections of control peGFP transfected cells, from section
16–61. The thickness of the optical sections is 3.9 nm.
Additional file 2: Figure S2. Transmission electron microscopy with
immunogold labeling. Transmission electron microscopy with
immunogold labeling of the purified VLPs by ultracentrifugation through
a sucrose cushion. Z-EGFP VLPs are pointed with red arrows, and similar
structures that are not immunogold labeled are pointed with empty
arrows. (The VLP indicated with * is amplified in Figure 2C). The bar
represents 100 nm.
Abbreviations
CMV: Cytomegalovirus; MVB: Multivesicular bodies; pDC: Plasmacytoid
dendritic cells; PML: Promyelocytic Leukemia Protein; TEM: Transmission
electron microscopy; VLP: Virus-like-particles.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
CSB carried out all the experiments and drafted the manuscript; MFB design
the molecular experiments and participated in the general direction; MHA
designed the Immunological tests and helped with the analysis and
interpretation of data; SEG participated in the design and realization of the
manuscript; JAI collaborated with the preparation of materials needed for all
assays; GG participated in the analysis and drafting of the manuscript; MEL
conceived the work and coordinated the drafting of the manuscript. All
authors read and approved the final manuscript.
Borio et al. BMC Biotechnology 2012, 12:80 Page 8 of 9
http://www.biomedcentral.com/1472-6750/12/80Authors’ information
CSB, MFB, MHA, SEG, JAI, GG, and MEL are research-professors of the
Universidad Nacional de Quilmes. CSB holds a doctoral fellowship of Consejo
Nacional de Ciencia y Tecnología (CONICET). MFB is member of the Research
Career of CONICET. SEG holds a postdoctoral fellowship of CONICET. JAI is
professor of the Universidad Nacional Arturo Jauretche. MEL is member of
the Research Career of CONICET.
Acknowledgements
This work was supported by research funds PICT2007-38138 and PICT2010-
0880 from Agencia Nacional de Promoción Científica y Técnica (ANPCyT), PIP
11420100100285 from CONICET, and PMMByAB from Universidad Nacional
de Quilmes. The plasmid pZ-eGFP was kindly provided by Dr. Agustin Ure
and Dr. Ricardo Gomez. The authors acknowledge Lic. Laura Esteban for her
help in the immunological assays, to the National Academy of Medicine for
their help in the confocal microscope assays, and to the collegues of
LIGBCM-AVI for their collaboration.
Author details
1LIGBCM-AVEZ. Department of Science and Technology, Universidad
Nacional de Quilmes, Bernal, Buenos Aires, Argentina. 2LIGBCM-AVI.
Department of Science and Technology, Universidad Nacional de Quilmes,
Bernal, Buenos Aires, Argentina. 3Laboratory of Immunology and Virology.
Department of Science and Technology, Universidad Nacional de Quilmes,
Roque Saenz Peña 352, Bernal, Buenos Aires B1876BXD, Argentina.
Received: 29 May 2012 Accepted: 25 October 2012
Published: 2 November 2012
References
1. Perez M, Craven RC, de la Torre JC: The small RING finger protein Z drives
arenavirus budding: implications for antiviral strategies. Proc Natl Acad
Sci USA 2003, 100(22):12978–12983.
2. Goni SE, Borio CS, Romano FB, Rota RP, Pilloff MG, Iserte JA, Tortorici MA,
Stephan BI, Bilen MF, Ghiringhelli PD, et al: Expression and purification of Z
protein from Junin virus. J Biomed Biotechnol 2010, 2010:970491.
3. Wilda M, Lopez N, Casabona JC, Franze-Fernandez MT: Mapping of the
tacaribe arenavirus Z-protein binding sites on the L protein identified
both amino acids within the putative polymerase domain and a region
at the N terminus of L that are critically involved in binding. J Virol 2008,
82(22):11454–11460.
4. Lopez N, Jacamo R, Franze-Fernandez MT: Transcription and RNA
replication of tacaribe virus genome and antigenome analogs require N
and L proteins: Z protein is an inhibitor of these processes. J Virol 2001,
75(24):12241–12251.
5. Neuman BW, Adair BD, Burns JW, Milligan RA, Buchmeier MJ, Yeager M:
Complementarity in the supramolecular design of arenaviruses and
retroviruses revealed by electron cryomicroscopy and image analysis. J
Virol 2005, 79(6):3822–3830.
6. Shtanko O, Imai M, Goto H, Lukashevich IS, Neumann G, Watanabe T,
Kawaoka Y: A role for the C terminus of Mopeia virus nucleoprotein in its
incorporation into Z protein-induced virus-like particles. J Virol 2010,
84(10):5415–5422.
7. Borden KL, Campbell Dwyer EJ, Salvato MS: An arenavirus RING (zinc-
binding) protein binds the oncoprotein promyelocyte leukemia protein
(PML) and relocates PML nuclear bodies to the cytoplasm. J Virol 1998,
72(1):758–766.
8. Kentsis A, Dwyer EC, Perez JM, Sharma M, Chen A, Pan ZQ, Borden KL: The
RING domains of the promyelocytic leukemia protein PML and the
arenaviral protein Z repress translation by directly inhibiting translation
initiation factor eIF4E. Journal Of Molecular Biology 2001, 312(4):609–623.
9. Urata S, de la Torre JC: Arenavirus budding. Adv Virol 2011, 2011:180326.
10. Strecker T, Eichler R, Meulen J, Weissenhorn W, Dieter Klenk H, Garten W,
Lenz O: Lassa virus Z protein is a matrix protein and sufficient for the
release of virus-like particles [corrected]. J Virol 2003, 77(19):10700–10705.
11. Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J: Cellular factors
required for Lassa virus budding. J Virol 2006, 80(8):4191–4195.
12. Eichler R, Strecker T, Kolesnikova L, ter Meulen J, Weissenhorn W, Becker S,
Klenk HD, Garten W, Lenz O: Characterization of the Lassa virus matrix
protein Z: electron microscopic study of virus-like particles and
interaction with the nucleoprotein (NP). Virus Res 2004, 100(2):249–255.13. Casabona JC, Levingston Macleod JM, Loureiro ME, Gomez GA, Lopez N:
The RING domain and the L79 residue of Z protein are involved in both
the rescue of nucleocapsids and the incorporation of glycoproteins into
infectious chimeric arenavirus-like particles. J Virol 2009, 83(14):7029–7039.
14. Urata S, Yasuda J, de la Torre JC: The z protein of the new world
arenavirus tacaribe virus has bona fide budding activity that does not
depend on known late domain motifs. J Virol 2009, 83(23):12651–12655.
15. Strecker T, Maisa A, Daffis S, Eichler R, Lenz O, Garten W: The role of
myristoylation in the membrane association of the Lassa virus matrix
protein Z. Virol J 2006, 3:93.
16. Perez M, Greenwald DL, de la Torre JC: Myristoylation of the RING finger Z
protein is essential for arenavirus budding. J Virol 2004,
78(20):11443–11448.
17. Chackerian B: Virus-like particles: flexible platforms for vaccine
development. Expert Rev Vaccines 2007, 6(3):381–390.
18. Roy P, Noad R: Virus-like particles as a vaccine delivery system: myths
and facts. Hum Vaccin 2008, 4(1):5–12.
19. McDonald B, Martin-Serrano J: No strings attached: the ESCRT machinery
in viral budding and cytokinesis. J Cell Sci 2009, 122(Pt 13):2167–2177.
20. Zhou W, Parent LJ, Wills JW, Resh MD: Identification of a membrane-
binding domain within the amino-terminal region of human
immunodeficiency virus type 1 Gag protein which interacts with acidic
phospholipids. J Virol 1994, 68(4):2556–2569.
21. Kentsis A, Gordon RE, Borden KL: Self-assembly properties of a model
RING domain. Proc Natl Acad Sci USA 2002, 99(2):667–672.
22. Ohkawa T, Volkman LE, Welch MD: Actin-based motility drives baculovirus
transit to the nucleus and cell surface. J Cell Biol 2010, 190(2):187–195.
23. Gladnikoff M, Shimoni E, Gov NS, Rousso I: Retroviral assembly and
budding occur through an actin-driven mechanism. Biophys J 2009,
97(9):2419–2428.
24. Capul AA, de la Torre JC: A cell-based luciferase assay amenable to high-
throughput screening of inhibitors of arenavirus budding. Virology 2008,
382(1):107–114.
25. Murphy FA, Webb PA, Johnson KM, Whitfield SG, Chappell WA: Arenoviruses
in Vero cells: ultrastructural studies. J Virol 1970, 6(4):507–518.
26. Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA,
Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, et al: Lassa virus-like
particles displaying all major immunological determinants as a vaccine
candidate for Lassa hemorrhagic fever. Virol J 2010, 7:279.
27. Ramqvist T, Andreasson K, Dalianis T: Vaccination, immune and gene
therapy based on virus-like particles against viral infections and cancer.
Expert Opin Biol Ther 2007, 7(7):997–1007.
28. Bachmann MF, Jennings GT: Vaccine delivery: a matter of size, geometry,
kinetics and molecular patterns. Nat Rev Immunol 2010, 10(11):787–796.
29. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel
RM: The influence of antigen organization on B cell responsiveness.
Science 1993, 262(5138):1448–1451.
30. Singh M, Chakrapani A, O'Hagan D: Nanoparticles and microparticles as
vaccine-delivery systems. Expert Rev Vaccines 2007, 6(5):797–808.
31. Szakal AK, Holmes KL, Tew JG: Transport of immune complexes from the
subcapsular sinus to lymph node follicles on the surface of
nonphagocytic cells, including cells with dendritic morphology.
J Immunol 1983, 131(4):1714–1727.
32. Carrasco YR, Batista FD: B cells acquire particulate antigen in a
macrophage-rich area at the boundary between the follicle and the
subcapsular sinus of the lymph node. Immunity 2007, 27(1):160–171.
33. Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, Fink K,
Henrickson SE, Shayakhmetov DM, Di Paolo NC, et al: Subcapsular sinus
macrophages in lymph nodes clear lymph-borne viruses and present
them to antiviral B cells. Nature 2007, 450(7166):110–114.
34. Qi H, Egen JG, Huang AY, Germain RN: Extrafollicular activation of lymph
node B cells by antigen-bearing dendritic cells. Science 2006,
312(5780):1672–1676.
35. Batista FD, Harwood NE: The who, how and where of antigen
presentation to B cells. Nat Rev Immunol 2009, 9(1):15–27.
36. Huang NN, Han SB, Hwang IY, Kehrl JH: B cells productively engage
soluble antigen-pulsed dendritic cells: visualization of live-cell dynamics
of B cell-dendritic cell interactions. J Immunol 2005, 175(11):7125–7134.
37. Link A, Zabel F, Schnetzler Y, Titz A, Brombacher F, Bachmann MF: Innate
immunity mediates follicular transport of particulate but not soluble
protein antigen. J Immunol 2012, 188(8):3724–3733.
Borio et al. BMC Biotechnology 2012, 12:80 Page 9 of 9
http://www.biomedcentral.com/1472-6750/12/8038. Bergtold A, Desai DD, Gavhane A, Clynes R: Cell surface recycling of
internalized antigen permits dendritic cell priming of B cells. Immunity
2005, 23(5):503–514.
39. Le Roux D, Le Bon A, Dumas A, Taleb K, Sachse M, Sikora R, Julithe M,
Benmerah A, Bismuth G, Niedergang F: Antigen stored in dendritic cells
after macropinocytosis is released unprocessed from late endosomes to
target B cells. Blood 2012, 119(1):95–105.
40. Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q: Virus-
like particle (VLP) lymphatic trafficking and immune response
generation after immunization by different routes. J Immunother 2009,
32(2):118–128.
41. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell
line transformed by DNA from human adenovirus type 5. J Gen Virol
1977, 36(1):59–74.
42. Arguelles MH, Orellana ML, Castello AA, Villegas GA, Masini M, Belizan AL,
Gonzalez Ayala S, Vera OD, Glikmann G: Measles virus-specific antibody
levels in individuals in Argentina who received a one-dose vaccine. J Clin
Microbiol 2006, 44(8):2733–2738.
doi:10.1186/1472-6750-12-80
Cite this article as: Borio et al.: Antigen vehiculization particles based on
the Z protein of Junin virus. BMC Biotechnology 2012 12:80.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
